Amid already plunging use of Merck’s Covid-19 antiviral Lagevrio, preprint gives look into real world performance
One day after the FDA granted Pfizer’s Paxlovid emergency use authorization in December, it did the same for Merck’s Covid-19 antiviral molnupiravir, marketed as Lagevrio …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
